Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Novo Nordisk A/SMerck & Co., Inc.AbbViePfizerNovartis
SymbolNYSE:NVONYSE:MRKNYSE:ABBVNYSE:PFENYSE:NVS
Price Information
Current Price$70.77$76.43$108.22$37.16$86.61
52 Week RangeHoldBuyBuyHoldHold
MarketRank™
Overall Score1.42.42.82.32.2
Analysis Score1.13.41.42.14.2
Community Score2.12.52.92.92.3
Dividend Score2.52.55.03.32.5
Ownership Score0.01.71.71.70.0
Earnings & Valuation Score1.31.93.11.31.9
Analyst Ratings
Consensus RecommendationHoldBuyBuyHoldHold
Consensus Price Target$72.00$95.92$115.75$38.57$108.50
% Upside from Price Target1.74% upside25.50% upside6.96% upside3.80% upside25.27% upside
Trade Information
Market Cap$166.65 billion$193.40 billion$190.99 billion$207.26 billion$198.22 billion
Beta0.460.430.840.70.59
Average Volume1,010,82411,827,9727,453,05832,317,4321,979,751
Sales & Book Value
Annual Revenue$18.30 billion$46.84 billion$33.27 billion$51.75 billion$47.50 billion
Price / Sales9.114.135.744.014.17
Cashflow$2.82 per share$6.21 per share$10.11 per share$4.14 per share$7.33 per share
Price / Cash25.1012.3110.708.9711.82
Book Value$3.65 per share$10.21 per share($5.53) per share$11.46 per share$24.53 per share
Price / Book19.397.49-19.573.243.53
Profitability
Net Income$5.84 billion$9.84 billion$7.88 billion$16.27 billion$11.73 billion
EPS$2.46$5.19$8.94$2.95$5.24
Trailing P/E Ratio26.6116.9122.8823.9728.03
Forward P/E Ratio23.9112.598.8912.1413.28
P/E Growth2.211.891.542.791.76
Net Margins32.65%24.33%18.16%17.85%14.71%
Return on Equity (ROE)71.46%53.83%439.24%24.88%24.39%
Return on Assets (ROA)31.34%16.83%13.22%9.32%10.59%
Dividend
Annual Payout$1.33$2.60$5.20$1.56$2.08
Dividend Yield1.88%3.40%4.81%4.20%2.40%
Three-Year Dividend Growth13.65%31.22%84.37%-10.94%13.60%
Payout Ratio54.07%50.10%58.17%52.88%39.69%
Years of Consecutive Dividend Growth1 Years1 Years49 Years1 Years1 Years
Debt
Debt-to-Equity Ratio0.04%0.90%5.38%0.76%0.49%
Current Ratio1.04%1.30%0.95%1.40%0.91%
Quick Ratio0.78%1.00%0.81%1.13%0.69%
Ownership Information
Institutional Ownership Percentage5.91%72.86%67.49%67.36%9.86%
Insider Ownership Percentage0.07%0.28%0.09%0.08%0.01%
Miscellaneous
Employees44,72373,00047,00088,300105,794
Shares Outstanding2.35 billion2.53 billion1.76 billion5.58 billion2.29 billion
Next Earnings Date5/5/2021 (Estimated)4/29/2021 (Confirmed)4/30/2021 (Confirmed)5/4/2021 (Confirmed)4/27/2021 (Confirmed)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
Gene therapies for neurodegenerative diseases: Pfizer, Novartis, Biogen and others seek more from FDA - Endpoints NewsGene therapies for neurodegenerative diseases: Pfizer, Novartis, Biogen and others seek more from FDA - Endpoints News
endpts.com - April 13 at 8:49 PM
FDA approves new self-injection administration for Xolair - PMLiVEFDA approves new self-injection administration for Xolair - PMLiVE
pmlive.com - April 13 at 3:49 PM
First Week of April 16th Options Trading For Novartis (NVS) - NasdaqFirst Week of April 16th Options Trading For Novartis (NVS) - Nasdaq
nasdaq.com - April 13 at 3:49 PM
Genentech and Novartis Win FDA Approval for Self-Injectable Form of Xolair - BioSpaceGenentech and Novartis Win FDA Approval for Self-Injectable Form of Xolair - BioSpace
biospace.com - April 13 at 3:49 PM
Novartis in Canada named a Top 50 Best Workplace™ in the country - Yahoo FinanceNovartis in Canada named a Top 50 Best Workplace™ in the country - Yahoo Finance
finance.yahoo.com - April 13 at 3:49 PM
NVS Named Top 10 SAFE International Dividend StockNVS Named Top 10 SAFE International Dividend Stock
nasdaq.com - April 13 at 9:19 AM
Delhi HC Restrains Eris Lifesciences from Infringing Novartis Sacubitril, Valsartan FDC - Medical DialoguesDelhi HC Restrains Eris Lifesciences from Infringing Novartis Sacubitril, Valsartan FDC - Medical Dialogues
medicaldialogues.in - April 12 at 5:57 PM
AACR: BeiGene details Novartis-partnered PD-1s first global pivotal win in lung cancer. Should Opdivo maker BMS be concerned? - FiercePharmaAACR: BeiGene details Novartis-partnered PD-1's first global pivotal win in lung cancer. Should Opdivo maker BMS be concerned? - FiercePharma
fiercepharma.com - April 12 at 5:57 PM
Novartis receives FDA approval of Xolair® (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients - PRNewswireNovartis receives FDA approval of Xolair® (omalizumab) self-injection with prefilled syringe across all indications for appropriate patients - PRNewswire
prnewswire.com - April 12 at 5:57 PM
Novartis wins injunction to stop generic version of blockbuster MS drug, for now - LawyerlyNovartis wins injunction to stop generic version of blockbuster MS drug, for now - Lawyerly
lawyerly.com.au - April 12 at 7:56 AM
Insights on the Myasthenia Gravis Drugs Global Market to 2027 - Featuring Novartis International, Pfizer & Shire Among Others - PRNewswireInsights on the Myasthenia Gravis Drugs Global Market to 2027 - Featuring Novartis International, Pfizer & Shire Among Others - PRNewswire
prnewswire.com - April 9 at 9:59 PM
Insights on the Myasthenia Gravis Drugs Global Market to 2027 - Featuring Novartis International, Pfizer & Shire Among Others - Yahoo FinanceInsights on the Myasthenia Gravis Drugs Global Market to 2027 - Featuring Novartis International, Pfizer & Shire Among Others - Yahoo Finance
finance.yahoo.com - April 9 at 4:58 PM
Regeneron Pharmaceuticals : Statement on Novartis Withdrawing Anti-VEGF Pre-Filled Syringe Case in the International Trade Commission - Marketscreener.comRegeneron Pharmaceuticals : Statement on Novartis Withdrawing Anti-VEGF Pre-Filled Syringe Case in the International Trade Commission - Marketscreener.com
marketscreener.com - April 9 at 4:58 PM
NOVARTIS AG : Receives a Sell rating from JP Morgan - marketscreener.comNOVARTIS AG : Receives a Sell rating from JP Morgan - marketscreener.com
marketscreener.com - April 9 at 6:57 AM
Novartis AG - Consensus Indicates Potential 21.3% Upside - DirectorsTalk InterviewsNovartis AG - Consensus Indicates Potential 21.3% Upside - DirectorsTalk Interviews
directorstalkinterviews.com - April 9 at 6:57 AM
Novartis (NVS) Teams Up With Artios for Radioligand Therapies - Yahoo FinanceNovartis (NVS) Teams Up With Artios for Radioligand Therapies - Yahoo Finance
finance.yahoo.com - April 8 at 10:45 PM
Novartis (NVS) Teams Up With Artios for Radioligand TherapiesNovartis (NVS) Teams Up With Artios for Radioligand Therapies
finance.yahoo.com - April 8 at 5:44 PM
Novartis now bags UK license for Kesimpta - The Pharma LetterNovartis now bags UK license for Kesimpta - The Pharma Letter
thepharmaletter.com - April 8 at 12:43 PM
Analysts Expect Novartis AG (NYSE:NVS) Will Post Earnings of $1.64 Per Share Analysts Expect Novartis AG (NYSE:NVS) Will Post Earnings of $1.64 Per Share
americanbankingnews.com - April 8 at 8:10 AM
Novartis AG (NYSE:NVS) Expected to Post Earnings of $1.64 Per ShareNovartis AG (NYSE:NVS) Expected to Post Earnings of $1.64 Per Share
americanbankingnews.com - April 8 at 8:10 AM
Novartis receives European and UK licence for Kesimpta® (ofatumumab), the first self-administered B-cell therapy for patients with relapsing forms of MS - PharmiWeb.comNovartis receives European and UK licence for Kesimpta® (ofatumumab), the first self-administered B-cell therapy for patients with relapsing forms of MS - PharmiWeb.com
pharmiweb.com - April 8 at 7:42 AM
Artios Pharma to collaborate with Novartis on DDR cancer therapies - EPM MagazineArtios Pharma to collaborate with Novartis on DDR cancer therapies - EPM Magazine
epmmagazine.com - April 8 at 7:42 AM
Novartis Taps Artios In Discovery Pact To Enhance Radioligand PortfolioNovartis Taps Artios In Discovery Pact To Enhance Radioligand Portfolio
finance.yahoo.com - April 7 at 2:40 PM
Videos | MedShr launches Global Health Programme backed by Novartis - Healthcare Global - Healthcare News, Magazine and WebsiteVideos | MedShr launches Global Health Programme backed by Novartis - Healthcare Global - Healthcare News, Magazine and Website
healthcareglobal.com - April 7 at 9:39 AM
Novartis UK announces further HRT patch stock issues - PharmaTimesNovartis UK announces further HRT patch stock issues - PharmaTimes
pharmatimes.com - April 7 at 9:39 AM
DateCompanyBrokerageAction
2/11/2021Novo Nordisk A/SUBS GroupReiterated Rating
2/4/2021Novo Nordisk A/SBarclaysReiterated Rating
1/20/2021Novo Nordisk A/SCredit Suisse GroupDowngrade
1/15/2021Novo Nordisk A/SDeutsche Bank AktiengesellschaftInitiated Coverage
11/12/2020Novo Nordisk A/SJPMorgan Chase & Co.Reiterated Rating
11/6/2020Novo Nordisk A/SMorgan StanleyDowngrade
11/3/2020Novo Nordisk A/SSociete GeneraleReiterated Rating
9/29/2020Novo Nordisk A/SBerenberg BankInitiated Coverage
7/6/2020Novo Nordisk A/SBank of AmericaDowngrade
5/4/2020Novo Nordisk A/SCowenInitiated Coverage
1/3/2020Novo Nordisk A/SGuggenheimDowngrade
11/22/2019Novo Nordisk A/SPareto SecuritiesDowngrade
9/17/2019Novo Nordisk A/SCitigroupUpgrade
2/5/2021Merck & Co., Inc.Cantor FitzgeraldReiterated Rating
12/6/2020Merck & Co., Inc.MizuhoReiterated Rating
11/10/2020Merck & Co., Inc.Sanford C. BernsteinReiterated Rating
10/29/2020Merck & Co., Inc.SVB LeerinkBoost Price Target
10/23/2020Merck & Co., Inc.TruistInitiated Coverage
8/4/2020Merck & Co., Inc.Royal Bank of CanadaReiterated Rating
8/3/2020Merck & Co., Inc.The Goldman Sachs GroupUpgrade
6/12/2020Merck & Co., Inc.Wolfe ResearchDowngrade
3/24/2020Merck & Co., Inc.ArgusLower Price Target
11/18/2020AbbVieBMO Capital MarketsInitiated Coverage
6/23/2020AbbVieAtlantic SecuritiesUpgrade
2/3/2021PfizerDZ BankReiterated Rating
9/23/2020NovartisOddo BhfDowngrade
(Data available from 4/13/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.